Core Viewpoint - Future Fuels Inc. is acquiring Hatchet Uranium Corp. (HUC) through a three-cornered amalgamation, enhancing its uranium exploration portfolio in the Athabasca Basin, a region known for its rich uranium deposits [1][2]. Company Overview - Future Fuels Inc. holds significant assets, including the Hornby Project in Nunavut and the Covette Project in Quebec, focusing on uranium exploration [23]. - ValOre Metals Corp. is a key player in this transaction, with HUC being a 51% owned subsidiary, indicating a strategic partnership aimed at capitalizing on uranium exploration opportunities [1][2]. Acquisition Details - The amalgamation agreement stipulates that HUC will amalgamate with Subco, with Future Fuels acquiring all outstanding securities of HUC [17]. - Each common share of HUC will be exchanged for 0.760836 of a common share in Future Fuels, and similar terms apply to HUC's warrants [17][20]. HUC Properties Summary - HUC holds interests in five claim blocks totaling approximately 97,674 hectares in the Wollaston Lake area, primarily within the Wollaston–Mudjatik Transition Zone [3]. - The Hatchet Lake Property, part of HUC's assets, covers about 13,711 hectares and has shown promising uranium readings, including up to 22,000 CPS and 1,637 ppm U [5][6]. Exploration History - HUC's properties have been explored since the late 1960s, employing various geological and geophysical methods, with recent advancements including the use of AI for target generation [4][6]. - The Highway Property, another asset, spans approximately 17,606 hectares and has identified uranium-bearing materials with readings up to 4,366 CPS and 230 ppm U [8][10]. Financial Aspects - The acquisition involves a financial advisory consulting agreement for a convertible debenture of $250,000, convertible into 5,000,000 HUC Shares prior to the acquisition completion [18][19]. - Upon completion, approximately 15,000,007 Consideration Shares and 1,104,743 Consideration Warrants will be issued to HUC's former securityholders [20]. Strategic Implications - The acquisition is expected to create a strong entity in the Canadian uranium exploration sector, enhancing market exposure and attracting capital for exploration programs [2].

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at ...

EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corre ...

GOLETA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, today announced that its CEO Jonathan Klamkin, Ph.D., and CFO Christopher Stewart will participate in the 38th Annual ROTH Conference on March 23, 2026 in Dana Point, California at the Ritz-Carlton Laguna Niguel. The management team will participate in one-on-ones and sma ...

Fourth Quarter Net Revenues Increased by 32.9% Year-over-Year to RMB12.8 Billion Fourth Quarter Average Monthly Transacting Customers Increased by 26.5% Year-over-Year to 98.4 Million 8,708 Net New Store Openings in 2025; Ending the Year with 31,048 Stores BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months and fiscal year ended December 31, 2025. FOURTH QUARTER 2025 HIGHLIGHTS1 Tot ...

- Full Year Revenues Increased 10.5% to a Record $983.6 Million Through Market Share Gains, GeographicalExpansion and Increased Demand for Vinyl Products - - Full Year Single-Family Residential Revenue Grew to a Record $403.4 Million - - Record Full Year Gross Profit of $421.4 Million, Representing 42.8% of Revenues - - Full Year Net Income of $159.6 Million, or $3.42 Per Diluted Share; Full Year Adjusted Net Income1 of $167.0 Million, or $3.58 Per Diluted Share - - Full Year Adjusted EBITDA1 of $291.3 Mill ...

KYIV, Ukraine, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Members of the Board of Directors of Kyivstar Group Ltd (“Kyivstar Group”; Nasdaq: KYIV;KYIVW), the parent company of JSC Kyivstar, Ukraine's leading digital operator and part of VEON Group (Nasdaq: VEON), visited the company's headquarters in Kyiv on the fourth anniversary of the full-scale war to meet with Ukrainian employees and reaffirm their unwavering support for Ukraine. VEON Founder Augie K Fabela II, the 70th US Secretary of State Mike Pompeo, Michie ...

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Ca ...

– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Data Monitoring Committee recommended initiation of Cohort 2 at the increased dose of 12 mg/kg in the ELEVATE-44-201 study – – Cash runway expected into Q3 2027 with $296 million in cash, cash equivalents and marketable securities as of December 31, 2025 – BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeu ...

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- ...